Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

@inproceedings{Cretella2014TrastuzumabEI,
  title={Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance},
  author={Daniele Cretella and Francesca Saccani and Federico Quaini and Caterina Frati and Costanza Annamaria Lagrasta and Mara A. Bonelli and Cristina Caffarra and Andrea Cavazzoni and Claudia Fumarola and Maricla Galetti and Silvia La Monica and Luca Ampollini and M Tiseo and Andrea Ardizzoni and Pier Giorgio Petronini and Roberta Alfieri},
  booktitle={Molecular Cancer},
  year={2014}
}
HER-2 represents a relatively new therapeutic target for non small cell lung cancer (NSCLC) patients. The incidence for reported HER-2 overexpression/amplification/mutations ranges from 2 to 20% in NSCLC. Moreover, HER-2 amplification is a potential mechanism of resistance to tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) (about 10% of cases). T-DM1, trastuzumab emtansine is an antibody-drug conjugate composed by the monoclonal antibody trastuzumab and the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Similar Papers

Loading similar papers…